Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

Published:2016-08-24 Issue:1 Volume:64 Page:25-31
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Moreno Lucas¹,Rubie Herve²,Varo Amalia¹,Le Deley Marie Cecile³,Amoroso Loredana⁴,Chevance Aurelie⁴,Garaventa Alberto⁵,Gambart Marion²,Bautista Francisco¹,Valteau-Couanet Dominique⁶,Geoerger Birgit⁶,Vassal Gilles⁶,Paoletti Xavier⁴,Pearson Andrew D. J.⁷

Affiliation:

1. HNJ-CNIO Clinical Research Unit; Hospital Universitario Niño Jesus; Madrid Spain

2. Hôpital des Enfants; CHU; Toulouse France

3. Universite Paris-Saclay, Univ. Paris-Sud, CESP, INSERM; Gustave Roussy; Villejuif France

4. Biostatistics Unit; Gustave Roussy; Villejuif France

5. Department of Pediatric Hemato-Oncology; Istituto Gianina, Gaslini; Genova

6. Department of Pediatric and Adolescent Oncology; Gustave Roussy; Villejuif France

7. Institute of Cancer Research; London UK

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference19 articles.

1. Recent advances in neuroblastoma;Maris;N Engl J Med,2010

2. At the frontier of progress for paediatric oncology: The neuroblastoma paradigm;Moreno;Br Med Bull,2013

3. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study;London;J Clin Oncol,2010

4. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment;Moroz;Trials,2014

5. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment;Brodeur;J Clin Oncol,1993

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial;Journal of Clinical Oncology;2024-01-08

2. Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study;Cancer;2023-12-15

3. Dispensing Oral Temozolomide in Children: Precision and Stability of a Novel and Ready to Use Liquid Formulation in Comparison with Capsule Derived Mixtures;Pharmaceutics;2023-11-30

4. A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules;Pharmaceutics;2023-11-24

5. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells;2023-11-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3